title: Pegylated interferon and ribavirin in haemodialysis patients.
authors.forename: A
authors.initials: A
authors.lastname: Bruchfeld
authors.forename: K
authors.initials: K
authors.lastname: Lindahl
authors.forename: O
authors.initials: O
authors.lastname: Reichard
authors.forename: T
authors.initials: T
authors.lastname: Carlsson
authors.forename: R
authors.initials: R
authors.lastname: Schvarcz
mesh_terms: D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage* / Q000009:adverse effects; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy*; D016133:Polymerase Chain Reaction; D012367:RNA, Viral / Q000032:analysis; D011994:Recombinant Proteins; D006435:Renal Dialysis; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin